81 results about "Humanized mouse" patented technology

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention discloses a preparation method and application of a sepsis-related encephalopathy model based on HLA II type gene humanized mice. According to the invention, HLA DP401 / DRA-IA beta- / -transgenic humanized mice are utilized, and the HLAII type gene humanized mouse sepsis model is prepared through mouse cecum seroperitoneal infection (CS) and meropenem intervention. The sepsis encephalopathy model can be comprehensively evaluated through indexes such as clinical score MSS, serum and hippocampal tissue inflammatory cytokine detection, hippocampal tissue microglial cell activation, hippocampal neuron spinous process change, transcriptomics, behavioral change and the like, and the sepsis encephalopathy model can be used for screening therapeutic drugs and therapeutic schedules; the HLA II type gene humanized mouse sepsis-related encephalopathy model provided by the invention can be used for infectious encephalopathy pathogenesis research, new drug research and development and safety evaluation.

The present disclosure provides transgenic mice for use as mouse models, and methods related thereto. The transgenic mice described herein comprise a humanized mouse telomerase (hmTert) gene included in a background mouse germline that provides shortened telomeres capable of reproducing humans and various human disease states.

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

The invention provides a construction method and application of a humanized MECP2 gene mouse model, and relates to the field of gene engineering. The model animal with the humanized hMECP2 gene is successfully prepared, the humanized hMECP2 protein can be normally expressed in the body of the model, and the model can be used for MECP2 gene function research and screening and evaluation of human MECP2 targeted drugs and therapies. The animal model prepared by the invention can be used for rapidly establishing more different MECP2 mutation humanized disease mouse models, and is applied to drug screening, drug effect research, related nervous system disease and tumor treatment and the like aiming at human MECP2 target sites, so that the research and development process of new drugs is accelerated, the time and the cost are saved, and the drug development risk is reduced. And a powerful tool is provided for researching the functions of the MECP2 protein and screening drugs.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.

The application discloses a method for constructing a CRBN gene humanized mouse model, which comprises replacing a knockout region of a mouse CRBN gene with a knock-in region of a human CRBN gene, so that the CRBN gene humanized mouse model is constructed, and the CRBN gene of the CRBN gene humanized mouse model is subjected to amino acid substitution of S369C, V380E, I391V and E431D. The application replaces a key functional domain of a mouse endogenous CRBN gene with a corresponding sequence of a human CRBN gene, so that the mouse can express a functional human CRBN protein, thereby solving the problem of lack of sensitivity of a wild-type mouse to a CRBN-dependent drug. The model provides an ideal preclinical experimental platform for studying the efficacy, toxicity and mechanism of action of a CRBN-related drug.

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises five structural domains, namely an antigen specific binding domain, a hinge domain, a transmembrane domain, a co-stimulation domain and a CD3 zeta signal transduction domain, the antigen specific binding structural domain can be specifically bound with an antigen comprising immune globulin IgE; the invention also provides an application of the immunoglobulin E in preparation of a long-acting medicine for treating IgE-mediated allergic diseases. Compared with the prior art, the application has the advantages that the anti-IgE monoclonal antibody is combined with a CAR-T technology, IgE protein generated in a targeting manner is converted into B cells generating IgE in a targeting manner, the killing effect of IgE CAR-T on mIgE + B cells is proved in in-vitro and in-vivo experiments, and the problems that the half-life period of a monoclonal antibody drug is short, and high-frequency medication is needed are solved. In addition, the invention also provides a scheme for carrying out an in-vivo experiment by utilizing the humanized mouse model, and successfully verifies the treatment effect of the CAR-T.

The present invention relates to the production of an ultra-advanced humanized mouse model based on umbilical cord blood-derived hematopoietic stem cell transplantation and immune cell expansion technology, and a method for producing same and, more specifically, to a humanized mouse based on human stem cell transplantation and immune boosting, which is produced by administering cephalosporin antibiotics, fluoroquinolone antibiotics, and vitamins to a mouse into which human stem cells have been transplanted, and to a method for producing same.

The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.

The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

A fully humanized mouse is immunized by using a BDCA-2 extracellular domain (ECD) antigen, positive clones are screened out through a hybridoma technology, and the specific monoclonal antibody targeting human plasma cell-like dendritic cells is obtained through gene sequencing and recombinant expression purification. The antibody disclosed by the invention has high binding capacity to human BDCA-2, and can be used for developing drugs or diagnostic reagents for treating or preventing inflammatory diseases or autoimmune diseases.

The invention relates to a construction method of a peripheral red blood cell humanized mouse, which comprises the following steps: transplanting human hematopoietic stem cells into the mouse and then applying a red blood cell inducer to the mouse, or applying a red blood cell inducer to the mouse and then infusing human red blood cells into the mouse. The red blood cell inducer comprises an antibody targeting mouse macrophage, dexamethasone or a derivative thereof, and a human macrophage colony stimulating factor. In a mouse transplanted with human hematopoietic stem cells, one or more of an antibody targeting mouse macrophages, dexamethasone and a human macrophage colony stimulating factor can be used in the red blood cell induced maturation process, and high-level human red blood cell reconstruction can be quickly realized within three weeks; the maturity and the denucleation ratio of peripheral human erythrocytes reconstructed in the mouse are completely consistent with those of normal human blood; in a mouse transplanted with human erythrocytes, the erythrocyte induction process can be single treatment of an antibody or dexamethasone, or combined use of the antibody and dexamethasone. The invention also provides application of the peripheral erythrocyte humanized mouse.

The invention relates to a method for screening and identifying metabolites and florae with a human immune regulation effect, which comprises the following steps: (1) establishing immune system humanized mice with multiple intestinal types, and analyzing the change of the florae, the metabolites and the immune system through intestinal flora sequencing, serum metabolome sequencing, flow cytometry and transcriptome sequencing; (2) determining the correlation and sequence between flora related metabolites and the change of the immune system through bioinformatics analysis; and (3) confirming the regulation and control relationship between the candidate metabolites and the immune subgroups in the step (2) through biological experiments. By means of the screening method, the chemical small molecule metabolites for regulating and controlling the human immune cells in the normal physiological state can be screened on a large scale, and the chemical small molecule metabolites can be developed into immunotherapy drugs or used as cell therapy drug culture system components. The screened propionic acid can promote cytotoxicity of T cells and CAR-T and secretion of related cytokines in the aspect of function regulation of the T cells, and the metabolite 2-hydroxybutyric acid is highly positively correlated with the Treg cells and can promote generation and functions of the Treg cells.

Provided herein are humanized mouse models generated using T cell-negative fractions or peripheral blood mononuclear cells obtained from T cell-negative fractions, and methods of using the mouse models to assess the efficacy and / or side effects of a therapeutic agent. Immune cell therapies require a large number of cells. Most commonly, the cells are collected using a process referred to as apheresis. Apheresis collection of the mononuclear cell (MNC) layer has been shown to be a safe and efficient method of collecting the large number of T cells.

The present application relates to a kind of construction method of atherosclerosis humanized mouse model, belong to genetic engineering and genetic modification technical field.The present application is first in ApoE and Ldlr double gene knockout mouse background and obtains NOD-4G gene knockout mouse by knockouting Prkdc and Il2rg gene in mouse, humanized atherosclerosis model is constructed by injecting human umbilical cord blood CD133+stem cell and high-fat feed feeding.Through to atherosclerosis degree analysis, it is found that the aorta and aortic root of the humanized atherosclerosis model constructed have a large number of plaque formation, and contain human CD45 + Leukocyte.This atherosclerosis humanized mouse model provides better animal genetic model for the analysis of the role of human immune cells in the occurrence and development of atherosclerosis disease, and has important significance for the research of human disease and the development of new therapy.

The invention discloses a method for implanting a cryopreserved human tissue into a mouse body, which comprises the following steps of: resuscitating the cryopreserved human tissue, implanting the cryopreserved human tissue into an immunodeficient mouse body, continuously feeding the mouse, and adding bFGF (basic fibroblast growth factor) and VEGFA (vascular endothelial growth factor A) when the cryopreserved human tissue is implanted. The invention further discloses a construction method of the cryopreserved tissue and immune system double-person-derived mouse model. The survival rate and structural integrity of the cryopreserved human tissue are remarkably improved by optimizing the size of a transplantation block, performing combined treatment on growth factors and other key technologies, so that the cryopreserved human tissue can be more effectively reconstructed in an immunodeficient mouse body, and a higher level of structural maturity is shown in histology. The two-person-derived mouse model constructed by combining cryopreserved tissues and an immune system can provide a better research platform for vaccine and efficacy evaluation.

The present disclosure provides a transgenic mouse as well as associated methods thereof for use as a mouse model. The transgenic mouse described herein comprises a humanized mouse telomerase (hmTert) gene contained in a background murine germline that provides shortened telomeres that can replicate humans and various human disease states.

Provided herein are humanized mouse models and methods for determining whether administration of engineered immune cell therapies likely elicit cytokine release syndrome and / or determining the efficacy of an anti-disease therapy. Further, the models provided herein may be used to test the efficacy of different anti-CRS therapies.

The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same.

The present invention discloses a method for enhancing the differentiation efficiency and survival duration of type I classical dendritic cells; during the induction process, by introducing the gene mycn, the present invention achieves a dual improvement in the induction efficiency of cDC1 and the survival of cDC cells. Through a humanized mouse tumor model, the greater effectiveness of the obtained mycn transgenic cDC1 for tumor treatment is verified.

The present invention discloses a humanized animal model for human influenza virus infection and a preparation method. The present invention provides a method for constructing a mouse model for human influenza virus infection, comprising the following steps: introducing the endothelial cell-specific promoter K18, the human sialyltransferase ST6GAL1 encoding gene, and the luciferase encoding gene into wild-type mice; subsequently breeding to obtain the F2 generation, which is a mouse model for human influenza virus infection; and each generation is subjected to genotyping and in vivo imaging identification. The present invention inserts the human ST6GAL1 gene into the mouse gene sequence, overexpresses the human sialyltransferase ST6GAL1 that synthesizes the human α2,6-linked sialic acid receptor, and constructs a mouse model for human influenza virus infection. The model can be directly infected with human influenza virus without the need for an in vivo adaptation process in mice, providing a humanized mouse model that conforms to the clinical characteristics of influenza for in-depth elucidation of the pathogenesis of influenza, verification of new drug targets, and development of new drugs and vaccine evaluation.

The present application relates to a kind of CD69 humanization mouse model construction method, the construction method: (1) the targeting vector of expression humanization CD69 gene is constructed;(2) design and obtain sgRNA for mouse Cd69 gene;(3) the targeting vector, sgRNA and Cas9 protein are co-injected or co-electrotransferred to mouse fertilized egg cytoplasm or nucleus, and the fertilized egg is transplanted to pseudopregnant mouse, and genotype identification is carried out to pseudopregnant litter mouse, and the positive F0 mouse of correct human source fragment successfully inserted is screened;(4)F0 mouse is mated with background mouse to obtain F1 mouse, and CD69 humanization mouse model is screened out.The CD69 humanization mouse constructed in the present application has application value in immunology and other fields.

This invention relates to a method for constructing a humanized FXI mouse model, comprising: (1) constructing a targeting vector expressing the humanized FXI gene; (2) designing and obtaining sgRNA targeting the mouse FXI gene; (3) co-injecting or co-electroporating the targeting vector, sgRNA, and Cas9 protein into the cytoplasm or nucleus of mouse zygotes, and transplanting the zygotes into pseudopregnant mice, performing genotyping on the pseudopregnant pups, and screening for positive F0 mice with the correct humanized fragment inserted; (4) mating the F0 mice with background mice to obtain F1 mice, and screening for the humanized FXI mouse model. The humanized FXI mouse constructed by this invention has broad application prospects in the coagulation system, thrombotic diseases, and related drug screening.

The application discloses a kind of targeted exosome chimeric antigen receptor molecules for treating HIV infection and its application, belong to the field of biological medicine technology.The application is packaged into targeted exosome by coding anti-HIV CAR mRNA directionally.The nano antibody sequence of targeted CD3, CD4, CD8+T receptor on T cell is fused to the N-terminal of LAMP-2B to construct specific targeting plasmid, so that the targeted peptide is expressed on the surface of exosome membrane, the expression plasmid containing RNA binding protein L7A and exosome tag protein CD63 is constructed, and the exosome loaded with CAR mRNA and targeted to T cell is obtained by three-plasmid co-transfection of HEK293F cells containing C / D box CAR plasmid.The exosome can construct human CAR-T cell when incubated with PBMC in vitro or back into humanized mouse in vivo, and has significant killing virus infected cell activity.

The invention relates to a humanized monoclonal antibody aiming at monkey pox virus and application of the humanized monoclonal antibody, human monkey pox virus antibodies B6R-16A1, B6R-21G7, B6R-22D12, B6R-22F9 and B6R-22H1 with high neutralization activity are obtained by screening memory B cells specifically combined with anti-B6R of a human antibody humanized mouse, and the human monkey pox virus antibodies have high neutralization activity. The monkey pox virus vaccine has the characteristics of strong combining capacity with monkey pox virus, good in-vitro neutrality, large affinity and in-vivo protection effect.

The invention discloses a construction method and application of an HRAS humanized mouse for carcinogenicity evaluation, and the construction method comprises the following steps: construction of a Tg-HRAS mouse: injecting a constructed vector into a mouse fertilized egg in a prokaryotic injection manner, randomly inserting a human HRAS gene segment containing an HRAS gene regulatory sequence and an expression sequence into a mouse genome, and constructing the Tg-HRAS mouse; the sequence fragment of the human HRAS gene is as shown in SEQ ID NO. 1; construction of a PMD18-T skeleton vector: taking the PMD18-T vector as a template, carrying out high-fidelity PCR (Polymerase Chain Reaction) amplification to obtain a 2.7 kb linearized PMD18-T vector, and carrying out gel recovery to serve as a skeleton of SLIC reaction; according to the construction method and application of the HRAS humanized mouse for carcinogenicity evaluation, by constructing the HRAS humanized mouse, carcinogenicity verification of the mouse is more efficient, the passing incidence rate is high, quick discovery can be achieved in the verification process, the purpose of shortening the verification period is achieved, the test cost is reduced, and the spontaneous tumor probability is high.